CN106728049A - It is a kind of to treat scorching Chinese and Western medicine composite preparation of chronic glomerulus and preparation method thereof - Google Patents
It is a kind of to treat scorching Chinese and Western medicine composite preparation of chronic glomerulus and preparation method thereof Download PDFInfo
- Publication number
- CN106728049A CN106728049A CN201611172244.3A CN201611172244A CN106728049A CN 106728049 A CN106728049 A CN 106728049A CN 201611172244 A CN201611172244 A CN 201611172244A CN 106728049 A CN106728049 A CN 106728049A
- Authority
- CN
- China
- Prior art keywords
- parts
- western medicine
- medicine composite
- composite preparation
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 54
- 238000002360 preparation method Methods 0.000 title claims abstract description 51
- 239000002131 composite material Substances 0.000 title claims abstract description 39
- 230000001684 chronic effect Effects 0.000 title claims abstract description 38
- VQEONGKQWIFHMN-UHFFFAOYSA-N Nordihydrocapsaicin Chemical compound COC1=CC(CNC(=O)CCCCCC(C)C)=CC=C1O VQEONGKQWIFHMN-UHFFFAOYSA-N 0.000 claims abstract description 38
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims abstract description 19
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims abstract description 19
- 240000007164 Salvia officinalis Species 0.000 claims abstract description 19
- LCXREBMNASQAOC-UHFFFAOYSA-N Worenine Chemical compound C1=C2C(C)=C(C=3C(=CC=4OCOC=4C=3)CC3)[N+]3=CC2=CC2=C1OCO2 LCXREBMNASQAOC-UHFFFAOYSA-N 0.000 claims abstract description 19
- 229940041616 menthol Drugs 0.000 claims abstract description 19
- 235000005412 red sage Nutrition 0.000 claims abstract description 19
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 claims abstract description 17
- 235000019743 Choline chloride Nutrition 0.000 claims abstract description 17
- LEQAKWQJCITZNK-AXHKHJLKSA-N N-[(7S)-1,2-dimethoxy-10-(methylthio)-9-oxo-3-[[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6,7-dihydro-5H-benzo[a]heptalen-7-yl]acetamide Chemical compound C1([C@@H](NC(C)=O)CCC2=C3)=CC(=O)C(SC)=CC=C1C2=C(OC)C(OC)=C3O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O LEQAKWQJCITZNK-AXHKHJLKSA-N 0.000 claims abstract description 17
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims abstract description 17
- 229960002079 calcium pantothenate Drugs 0.000 claims abstract description 17
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 claims abstract description 17
- 229960003178 choline chloride Drugs 0.000 claims abstract description 17
- 229960000287 thiocolchicoside Drugs 0.000 claims abstract description 17
- 239000002994 raw material Substances 0.000 claims abstract description 12
- 239000000203 mixture Substances 0.000 claims abstract description 11
- 241000227129 Aconitum Species 0.000 claims description 18
- 238000002156 mixing Methods 0.000 claims description 15
- 238000001035 drying Methods 0.000 claims description 7
- 239000012467 final product Substances 0.000 claims description 7
- 238000007873 sieving Methods 0.000 claims description 7
- 229940086735 succinate Drugs 0.000 claims description 7
- 229910021642 ultra pure water Inorganic materials 0.000 claims description 7
- 239000012498 ultrapure water Substances 0.000 claims description 7
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
- 239000005864 Sulphur Substances 0.000 claims description 2
- KEIZXGINFPDITQ-UHFFFAOYSA-N UNPD138008 Natural products C1=C(O)C(OC)=CC=C1C1=C(OC2C(C(O)C(O)C(COC3C(C(O)C(O)C(C)O3)O)O2)O)C(=O)C2=C(O)C=C(O)C=C2O1 KEIZXGINFPDITQ-UHFFFAOYSA-N 0.000 claims 1
- 238000005660 chlorination reaction Methods 0.000 claims 1
- 229960001231 choline Drugs 0.000 claims 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims 1
- UIDGLYUNOUKLBM-GEBJFKNCSA-N isorhamnetin-3-O-rutinoside Chemical compound C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]3[C@@H]([C@H](O)[C@@H](O)[C@H](C)O3)O)O2)O)=C1 UIDGLYUNOUKLBM-GEBJFKNCSA-N 0.000 claims 1
- BGLPQQKZNUKSAR-UHFFFAOYSA-N isorhamnetin-3-O-rutinoside Natural products COc1ccc(cc1O)C2=C(OC3OC(COCC4OC(O)C(O)C(O)C4O)C(O)C(O)C3O)C(=O)c5c(O)cc(O)cc5O2 BGLPQQKZNUKSAR-UHFFFAOYSA-N 0.000 claims 1
- IEPKWJCBNGNVDF-UHFFFAOYSA-N narcissin Natural products OC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)OC2C(C(O)C(O)C(COC3C(C(O)C(O)C(C)O3)O)O2)O)=C1 IEPKWJCBNGNVDF-UHFFFAOYSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 9
- 229940079593 drug Drugs 0.000 abstract description 6
- 230000007774 longterm Effects 0.000 abstract description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract description 2
- 230000007246 mechanism Effects 0.000 abstract description 2
- 230000006641 stabilisation Effects 0.000 abstract description 2
- 238000011105 stabilization Methods 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 241000173529 Aconitum napellus Species 0.000 abstract 1
- 210000002700 urine Anatomy 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 6
- 206010030113 Oedema Diseases 0.000 description 5
- 230000003902 lesion Effects 0.000 description 5
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 4
- 208000020832 chronic kidney disease Diseases 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 230000003907 kidney function Effects 0.000 description 4
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 229940109239 creatinine Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 206010001580 Albuminuria Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 231100001252 long-term toxicity Toxicity 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000022461 Glomerular disease Diseases 0.000 description 1
- 231100000111 LD50 Toxicity 0.000 description 1
- 240000001307 Myosotis scorpioides Species 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 231100000160 chronic toxicity Toxicity 0.000 description 1
- 230000007665 chronic toxicity Effects 0.000 description 1
- 231100000132 chronic toxicity testing Toxicity 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 231100000852 glomerular disease Toxicity 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- YOEWQQVKRJEPAE-UHFFFAOYSA-L succinylcholine chloride (anhydrous) Chemical compound [Cl-].[Cl-].C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C YOEWQQVKRJEPAE-UHFFFAOYSA-L 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/714—Aconitum (monkshood)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Botany (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The scorching Chinese and Western medicine composite preparation of chronic glomerulus is treated the invention discloses a kind of, the scorching Chinese and Western medicine composite preparation of the treatment chronic glomerulus is according to the primary raw material of weight portion：18 30 parts of the red sage root, 5 15 parts of monkshood, 8 12 parts of Ke Nuoxin, 5 12 parts of nordihydrocapsaicin, 48 parts of Thiocolchicoside, 26 parts of Choline Chloride Succinate, 28 parts of menthol, 7 14 parts of calcium pantothenate, 5 18 parts of worenine.Medicine of the present invention is strictly selected material composition according to the scorching understanding mechanism of chronic glomerulus, so as to reach the purpose of comprehensive rehabilitation, with rapid-action, effect stabilization, carry convenient to take, long-term taking and have no toxic side effect the characteristics of.
Description
Technical field
It is specifically a kind of to treat the compound system of the scorching Chinese and Western medicine of chronic glomerulus the present invention relates to a kind of field of medicine preparation
Agent.
Background technology
CGN (chronic glomerulonephritis), referred to as chronic nephritis, mean albuminuria,
Blood urine, hypertension, oedema are basic clinical, and mode of onset is had nothing in common with each other, and protracted inflammation, lesion is slowly in progress, so that not
With degree renal hypofunction, one group of renal glomerular disease of chronic renal failure is finally developed into.Due to this group of histological type of disease
And stadium is different, main clinical manifestation is different, and disease performance is in variation.The treatment chronic glomerulus of current Clinical practice
The Chinese patent drug of ephritis is divided into two major classes：One is monomer component such as Chinese caterpillar fungus bacterial filament preparation；Another kind of is Chinese medicine compound prescription such as compound
Kidney inflammation tablets etc..Previous class mainly shields to kidney local damage, it is impossible to for the clinic of patients with chronic kidney disease
Performance is treated；Clinical manifestation of the latter class to Patients with Chronic Kidney Disease has certain effect, but CKD kidney part
Pathological change be generally activity lesion and inactive lesion and deposit, activity lesion cannot be controlled, though clinical manifestation is slow
Property process, and be in progress progressive until develop into uremia by kidney lesion in itself.
The content of the invention
The scorching Chinese and Western medicine composite preparation of chronic glomerulus is treated it is an object of the invention to provide a kind of, to solve the above-mentioned back of the body
The problem proposed in scape technology.
To achieve the above object, the present invention provides following technical scheme：
It is a kind of to treat the scorching Chinese and Western medicine composite preparation of chronic glomerulus, be according to the primary raw material of weight portion：Red sage root 18-30
Part, monkshood 5-15 parts, Ke Nuoxin 8-12 parts, nordihydrocapsaicin 5-12 parts, Thiocolchicoside 4-8 parts, Choline Chloride Succinate 2-6
Part, menthol 2-8 parts, calcium pantothenate 7-14 parts, worenine 5-18 parts.
As further scheme of the invention：The scorching Chinese and Western medicine composite preparation of the treatment chronic glomerulus, according to weight
Part primary raw material be：Red sage root 21-27 parts, monkshood 8-12 parts, Ke Nuoxin 9-11 parts, nordihydrocapsaicin 7-11 parts, sulphur autumn waters -- limid eyes
Celestial glycosides 4-8 parts, Choline Chloride Succinate 2-6 parts, menthol 2-8 parts, calcium pantothenate 8-12 parts, worenine 9-14 parts.
As further scheme of the invention：The scorching Chinese and Western medicine composite preparation of the treatment chronic glomerulus, according to weight
Part primary raw material be：25 parts of the red sage root, 10 parts of monkshood, 10 parts of Ke Nuoxin, 9 parts of nordihydrocapsaicin, 6 parts of Thiocolchicoside, chlorine
Change 4 parts of Scoline, 5 parts of menthol, 10 parts of calcium pantothenate, 12 parts of worenine.
A kind of preparation method for treating the scorching Chinese and Western medicine composite preparation of chronic glomerulus, concretely comprises the following steps：
First, in pharmaceutical grade clean area, by above-mentioned metering ratio weigh the red sage root, monkshood, Ke Nuoxin, nordihydrocapsaicin,
Thiocolchicoside, Choline Chloride Succinate, menthol, calcium pantothenate, worenine, sieving, machinery add ultra-pure water after mixing, and put
In putting pharmacy mixer, mix 4-8min, control RSD≤5%, compressing tablet and low temperature drying after mixing, temperature control at 4-8 DEG C,
Packaging obtains final product the scorching Chinese and Western medicine composite preparation for the treatment of chronic glomerulus.
As further scheme of the invention：Mix 6min in specific steps.
Compared with prior art, the beneficial effects of the invention are as follows：
Medicine of the present invention is strictly selected material composition according to the scorching understanding mechanism of chronic glomerulus, complete so as to reach
The purpose of face rehabilitation, with rapid-action, effect stabilization, carry convenient to take, long-term taking and have no toxic side effect the characteristics of.
Specific embodiment
Below in conjunction with the embodiment of the present invention, the technical scheme in the embodiment of the present invention is clearly and completely described,
Obviously, described embodiment is only a part of embodiment of the invention, rather than whole embodiments.Based in the present invention
Embodiment, the every other embodiment that those of ordinary skill in the art are obtained under the premise of creative work is not made, all
Belong to the scope of protection of the invention.
Embodiment 1
It is a kind of to treat the scorching Chinese and Western medicine composite preparation of chronic glomerulus, be according to the primary raw material of weight portion：18 parts of the red sage root,
It is 5 parts of monkshood, 8 parts of Ke Nuoxin, 5 parts of nordihydrocapsaicin, 4 parts of Thiocolchicoside, 2 parts of Choline Chloride Succinate, 2 parts of menthol, general
7 parts of sour calcium, 5 parts of worenine.
A kind of preparation method for treating the scorching Chinese and Western medicine composite preparation of chronic glomerulus, concretely comprises the following steps：
First, in pharmaceutical grade clean area, by above-mentioned metering ratio weigh the red sage root, monkshood, Ke Nuoxin, nordihydrocapsaicin,
Thiocolchicoside, Choline Chloride Succinate, menthol, calcium pantothenate, worenine, sieving, machinery add ultra-pure water after mixing, and put
Put in pharmacy mixer, mix 4min, control RSD≤5%, compressing tablet and low temperature drying after mixing, temperature control are packed at 4 DEG C
Obtain final product the scorching Chinese and Western medicine composite preparation for the treatment of chronic glomerulus.
Embodiment 2
It is a kind of to treat the scorching Chinese and Western medicine composite preparation of chronic glomerulus, be according to the primary raw material of weight portion：21 parts of the red sage root,
It is 8 parts of monkshood, 9 parts of Ke Nuoxin, 7 parts of nordihydrocapsaicin, 4 parts of Thiocolchicoside, 2 parts of Choline Chloride Succinate, 2 parts of menthol, general
8 parts of sour calcium, 9 parts of worenine.
A kind of preparation method for treating the scorching Chinese and Western medicine composite preparation of chronic glomerulus, concretely comprises the following steps：
First, in pharmaceutical grade clean area, by above-mentioned metering ratio weigh the red sage root, monkshood, Ke Nuoxin, nordihydrocapsaicin,
Thiocolchicoside, Choline Chloride Succinate, menthol, calcium pantothenate, worenine, sieving, machinery add ultra-pure water after mixing, and put
Put in pharmacy mixer, mix 4min, control RSD≤5%, compressing tablet and low temperature drying after mixing, temperature control are packed at 4 DEG C
Obtain final product the scorching Chinese and Western medicine composite preparation for the treatment of chronic glomerulus.
Embodiment 3
It is a kind of to treat the scorching Chinese and Western medicine composite preparation of chronic glomerulus, be according to the primary raw material of weight portion：25 parts of the red sage root,
10 parts of monkshood, 10 parts of Ke Nuoxin, 9 parts of nordihydrocapsaicin, 6 parts of Thiocolchicoside, 4 parts of Choline Chloride Succinate, 5 parts of menthol,
10 parts of calcium pantothenate, 12 parts of worenine.
A kind of preparation method for treating the scorching Chinese and Western medicine composite preparation of chronic glomerulus, concretely comprises the following steps：
First, in pharmaceutical grade clean area, by above-mentioned metering ratio weigh the red sage root, monkshood, Ke Nuoxin, nordihydrocapsaicin,
Thiocolchicoside, Choline Chloride Succinate, menthol, calcium pantothenate, worenine, sieving, machinery add ultra-pure water after mixing, and put
Put in pharmacy mixer, mix 6min, control RSD≤5%, compressing tablet and low temperature drying after mixing, temperature control are packed at 6 DEG C
Obtain final product the scorching Chinese and Western medicine composite preparation for the treatment of chronic glomerulus.
Embodiment 4
It is a kind of to treat the scorching Chinese and Western medicine composite preparation of chronic glomerulus, be according to the primary raw material of weight portion：27 parts of the red sage root,
12 parts of monkshood, 11 parts of Ke Nuoxin, 11 parts of nordihydrocapsaicin, 8 parts of Thiocolchicoside, 6 parts of Choline Chloride Succinate, 8 parts of menthol,
12 parts of calcium pantothenate, 14 parts of worenine.
A kind of preparation method for treating the scorching Chinese and Western medicine composite preparation of chronic glomerulus, concretely comprises the following steps：
First, in pharmaceutical grade clean area, by above-mentioned metering ratio weigh the red sage root, monkshood, Ke Nuoxin, nordihydrocapsaicin,
Thiocolchicoside, Choline Chloride Succinate, menthol, calcium pantothenate, worenine, sieving, machinery add ultra-pure water after mixing, and put
Put in pharmacy mixer, mix 8min, control RSD≤5%, compressing tablet and low temperature drying after mixing, temperature control are packed at 8 DEG C
Obtain final product the scorching Chinese and Western medicine composite preparation for the treatment of chronic glomerulus.
Embodiment 5
It is a kind of to treat the scorching Chinese and Western medicine composite preparation of chronic glomerulus, be according to the primary raw material of weight portion：30 parts of the red sage root,
15 parts of monkshood, 12 parts of Ke Nuoxin, 12 parts of nordihydrocapsaicin, 8 parts of Thiocolchicoside, 6 parts of Choline Chloride Succinate, 8 parts of menthol,
14 parts of calcium pantothenate, 18 parts of worenine.
A kind of preparation method for treating the scorching Chinese and Western medicine composite preparation of chronic glomerulus, concretely comprises the following steps：
First, in pharmaceutical grade clean area, by above-mentioned metering ratio weigh the red sage root, monkshood, Ke Nuoxin, nordihydrocapsaicin,
Thiocolchicoside, Choline Chloride Succinate, menthol, calcium pantothenate, worenine, sieving, machinery add ultra-pure water after mixing, and put
Put in pharmacy mixer, mix 8min, control RSD≤5%, compressing tablet and low temperature drying after mixing, temperature control are packed at 8 DEG C
Obtain final product the scorching Chinese and Western medicine composite preparation for the treatment of chronic glomerulus.
Pharmacology test
1st, chronic toxicity test
It is experiment with Chinese and Western medicine composite preparation obtained in the embodiment of the present invention 3, using gastric infusion mode, connects in 24h
Continuous administration 3 times, per minor tick 6h, is administered 500mg/kg doses every time, and daily accumulation medicine total amount reaches 1500mg medicines/kg, phase
When in 100 times of people's quantity.After administration in 7d, mouse activity, feed, excretion are normal, well-grown, hair color light,
Its average weight increases with the extension of experimental period.Every mouse of post mortem at 8d, visually observe the heart, liver, spleen,
Lung, kidney, brain, thymus gland, stomach, intestines etc. do not find color and paramophia, fail to measure median lethal dose (LD50).As a result table
It is bright：Chinese and Western medicine composite preparation of the present invention is without chronic toxicity.
2nd, long term toxicity test
It is experiment with Chinese and Western medicine composite preparation obtained in the embodiment of the present invention 3, using gastric infusion mode, by the present invention
Western medicine compound formulation is divided into low dosage, middle dosage, three groups of high dose, the drug dose of each group is respectively 150,300,450mg medicines
Thing/kg/d, 10,20,30 times equivalent to clinical dosage.After gastric infusion 24 weeks, medicine of the present invention to the general status of animal,
, without obvious influence, Systematic anatomy, organ coefficient and histopathological examination are not sent out yet for hematological indices, blood parameters
Existing abnormal pathologic changes.It is discontinued 2 weeks and also has no substantially change.Result shows：Chinese and Western medicine composite preparation of the present invention is in long term toxicity
In experiment, overt toxicity reaction and delayed toxicity reaction are not found.It can be seen that, medicine composite preparation non-toxic reaction in Chinese and Western of the present invention,
Long-term prescription is safe and reliable.
3rd, clinical test
Accept the patient for meeting Western medicine diagnostic criteria for medical treatment, totally 92 patients, male 43, women 49, average age 42.5
Year, average course of disease 1.7 years, 1.32 ± 0.63g/d of urine albumen amount, 7.64 ± 1.22mmol/L of blood urea nitrogen, serum creatinine 168.41
±51.32μmol/L。
Western medicine diagnostic criteria：(1) onset is slow, protracted inflammation, when it is light when weight, renal function progressively goes down, blood urea nitrogen, blood
Creatinine is slightly raised；(2) there is different degrees of albuminuria (quantity of proteinuria>1g/24h), blood urine, oedema and hypertension；(3) disease
Cheng Zhongke induces chronic seizures because of reasons such as respiratory tract infection, the performance for similar chronic nephritis occur.
Curative effect judging standard：1. complete incidence graph：Edema, pain in the back are wholly absent, and Urine proteins continue feminine gender, twenty-four-hour urine albumen
Quantitative continuous are less than 0.3g, normal renal function；2. it is basic to alleviate：Edema disappears substantially with pain in the back, and Urine proteins persistently reduce 50%
More than, normal renal function or normal (being differed with normal value no more than 15%)；3. effective：Oedema is clearly better with pain in the back,
Twenty-four-hour urine protein content persistently reduces 25%~49%, normal renal function or has improvement；4. invalid：Clinical manifestation shows and laboratory
Inspection is not improved or adds severe one on the contrary.
Therapeutic effect：92 patients are treated using Chinese and Western medicine composite preparation prepared by the embodiment of the present invention 3, daily clothes
With 15mg/kg, after treating 30 days, 0.54 ± 0.82g/d of urine albumen amount, 7.04 ± 1.32mmol/L of blood urea nitrogen, serum creatinine
There is significant difference before 121.65 ± 69.29 μm of ol/L, with treatment；Complete incidence graph 45, basic alleviation 21, effective 23,
Invalid 3, total effective rate 96.7%；And do not occur adverse reaction during whole treatment.
It is obvious to a person skilled in the art that the invention is not restricted to the details of above-mentioned one exemplary embodiment, Er Qie
In the case of without departing substantially from spirit or essential attributes of the invention, the present invention can be in other specific forms realized.Therefore, no matter
From the point of view of which point, embodiment all should be regarded as exemplary, and be nonrestrictive, the scope of the present invention is by appended power
Profit requires to be limited rather than described above, it is intended that all in the implication and scope of the equivalency of claim by falling
Change is included in the present invention.
Moreover, it will be appreciated that although the present specification is described in terms of embodiments, not each implementation method is only wrapped
Containing an independent technical scheme, this narrating mode of specification is only that for clarity, those skilled in the art should
Specification an as entirety, the technical scheme in each embodiment can also be formed into those skilled in the art through appropriately combined
May be appreciated other embodiment.
Claims (5)
1. it is a kind of to treat the scorching Chinese and Western medicine composite preparation of chronic glomerulus, it is characterised in that the primary raw material according to weight portion is：
Red sage root 18-30 parts, monkshood 5-15 parts, Ke Nuoxin 8-12 parts, nordihydrocapsaicin 5-12 parts, Thiocolchicoside 4-8 parts, chlorination amber
2-6 parts, menthol 2-8 parts, calcium pantothenate 7-14 parts, worenine 5-18 parts of amber choline.
2. it is according to claim 1 to treat the scorching Chinese and Western medicine composite preparation of chronic glomerulus, it is characterised in that the treatment
The scorching Chinese and Western medicine composite preparation of chronic glomerulus, be according to the primary raw material of weight portion：Red sage root 21-27 parts, monkshood 8-12 parts, Ke
Promise is pungent 9-11 parts, nordihydrocapsaicin 7-11 parts, Thiocolchicoside 4-8 parts, Choline Chloride Succinate 2-6 parts, menthol 2-8 parts,
Calcium pantothenate 8-12 parts, worenine 9-14 parts.
3. it is according to claim 1 and 2 to treat the scorching Chinese and Western medicine composite preparation of chronic glomerulus, it is characterised in that described
The scorching Chinese and Western medicine composite preparation for the treatment of chronic glomerulus, be according to the primary raw material of weight portion：25 parts of the red sage root, 10 parts of monkshood, Ke
Pungent 10 parts of promise, 9 parts of nordihydrocapsaicin, 6 parts of Thiocolchicoside, 4 parts of Choline Chloride Succinate, 5 parts of menthol, 10 parts of calcium pantothenate,
12 parts of worenine.
4. the preparation method of the scorching Chinese and Western medicine composite preparation of a kind for the treatment of chronic glomerulus as described in claim 1-3 is any,
Characterized in that, concretely comprising the following steps：
First, in pharmaceutical grade clean area, the red sage root, monkshood, Ke Nuoxin, nordihydrocapsaicin, sulphur autumn are weighed by above-mentioned metering ratio
Narcissin, Choline Chloride Succinate, menthol, calcium pantothenate, worenine, sieving, machinery add ultra-pure water after mixing, place system
In medicine mixer, mix 4-8min, control RSD≤5%, compressing tablet and low temperature drying after mixing, temperature control are packed at 4-8 DEG C
Obtain final product the scorching Chinese and Western medicine composite preparation for the treatment of chronic glomerulus.
5. the preparation method of the scorching Chinese and Western medicine composite preparation for the treatment of chronic glomerulus according to claim 4, its feature exists
In mixing 6min in specific steps.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611172244.3A CN106728049A (en) | 2016-12-17 | 2016-12-17 | It is a kind of to treat scorching Chinese and Western medicine composite preparation of chronic glomerulus and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611172244.3A CN106728049A (en) | 2016-12-17 | 2016-12-17 | It is a kind of to treat scorching Chinese and Western medicine composite preparation of chronic glomerulus and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106728049A true CN106728049A (en) | 2017-05-31 |
Family
ID=58892148
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611172244.3A Pending CN106728049A (en) | 2016-12-17 | 2016-12-17 | It is a kind of to treat scorching Chinese and Western medicine composite preparation of chronic glomerulus and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106728049A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101204481A (en) * | 2007-12-17 | 2008-06-25 | 牟培超 | Chinese traditional medicine for chronic nephritis |
| CN101615222A (en) * | 2008-06-23 | 2009-12-30 | 中国医学科学院放射医学研究所 | A kind of Chinese prescription designing technique based on the Chinese medicine effective component group |
-
2016
- 2016-12-17 CN CN201611172244.3A patent/CN106728049A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101204481A (en) * | 2007-12-17 | 2008-06-25 | 牟培超 | Chinese traditional medicine for chronic nephritis |
| CN101615222A (en) * | 2008-06-23 | 2009-12-30 | 中国医学科学院放射医学研究所 | A kind of Chinese prescription designing technique based on the Chinese medicine effective component group |
Non-Patent Citations (7)
| Title |
|---|
| 俞雯雯等: "泛素化调控与中药抗炎", 《医学综述》 * |
| 傅志贤等: "香草酸受体调节剂", 《药学进展》 * |
| 刘慧琼等: "大叶钩藤中柯诺辛碱的含量测定", 《时珍国医国药》 * |
| 廖传德: "泛酸钙维生素E合并治疗结节性血管炎", 《武汉医学杂志》 * |
| 杨仁仪: "神经肌肉松弛剂在机械通气中的应用", 《中国实用儿科杂志》 * |
| 王勇: "《辨质辨病临床应用手册——中西医结合快速诊疗六十病》", 3 September 2014, 中医古籍出版社 * |
| 陈婷等: "芳香类药用植物抗炎镇痛活性成分及其作用机制研究进展", 《中草药》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105381039B (en) | A kind of Chinese medicine composition and preparation method thereof for treating primary osteoporosis | |
| CN106728049A (en) | It is a kind of to treat scorching Chinese and Western medicine composite preparation of chronic glomerulus and preparation method thereof | |
| CN108434201A (en) | Treat the Chinese medicine composition and preparation method thereof of lumbocrural pain | |
| CN106668600A (en) | Composite preparation for treating chronic glomerulitis | |
| CN106619650A (en) | Compound preparation for treating chronic glomerulitis | |
| CN104000919B (en) | A kind of Chinese medicine composition | |
| JP2001086953A (en) | Analgesic food for assisting health | |
| CN106822133A (en) | A kind of Western medicine compound for treating acute diarrhea | |
| CN106668048A (en) | Western medicine for treating diffuse fibrosis of lung | |
| CN106727632A (en) | A kind of compound formulation for treating acute glomerulonephritis | |
| CN106822239A (en) | It is a kind of to treat Chinese and western medicinal composition of the infection of the upper respiratory tract and preparation method thereof | |
| CN106727883A (en) | It is a kind of to treat Chinese and Western medicine composite preparation of acute glomerulonephritis and preparation method thereof | |
| CN107198692A (en) | Application of the Acankoreanogenia A in treatment diabetes medicament is prepared | |
| CN106692264A (en) | Compound preparation for treating acute glomerulitis | |
| KR100584214B1 (en) | The method of manufacturing potentiator using oyster shell powder | |
| CN106511440A (en) | Compound Chinese and Western medicine composition for treating chronic dysentery and preparation method thereof | |
| CN106727642A (en) | A kind of children's antipyretic | |
| CN104586826B (en) | Levocarnitine and its derivative are preparing the application in treating or preventing idiopathic pulmonary fibrosis drug | |
| CN117379451A (en) | Combined medicine for treating acute liver failure and/or hepatic encephalopathy and application thereof | |
| CN105796693B (en) | A kind of pharmaceutical composition and its preparation method and application preventing and treating Diphterin type pox | |
| CN106266555A (en) | A kind of Chinese medicine composition treating few essence, azoospermia | |
| CN105125704B (en) | A kind of compositions purposes in the medicine of preparation treatment gout | |
| CN106581038A (en) | Asthma treatment medicine | |
| CN106727502A (en) | A kind of Western medicine for treating hypoxemia respiratory failure type | |
| CN106727508A (en) | A kind of combination drug for treating chronic dysentery |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170531 |
|
| RJ01 | Rejection of invention patent application after publication |